CD8A and melanoma: The VLP‐based vaccine was designed by linking the melanoma differentiation specific antigen Melan‐A/Mart1 (The HLA‐A2 restricted epitope extended by a few amino acids) to Qβ‐VLPs which were additionally packaged with the TLR‐9 ligand G10 (a type‐A CpG) as an adjuvant for effective stimulation of DCs and CD8+ T cells (Speiser et al., 2010).